# Julia B. Lewis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/julia-b-lewis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 40,364 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 60 |
| i10-index | 122 |
| Last Known Institution | Vanderbilt University Medical Center |
| OpenAlex ID | https://openalex.org/A5055479743 |
| ORCID iD | https://orcid.org/0000-0002-1530-7115 |
| Works | 201 |

## Researcher papers

- [A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation](https://scholariq.org/papers/a-more-accurate-method-to-estimate-glomerular-filtration-rate-from-serum/)
- [Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes](https://scholariq.org/papers/renoprotective-effect-of-the-angiotensin-receptor-antagonist-irbesartan-in/)
- [Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-recent-worsening-heart-failure/)
- [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease/)
- [Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/aliskiren-combined-with-losartan-in-type-2-diabetes-and-nephropathy/)
- [Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis](https://scholariq.org/papers/pharmacological-blood-pressure-lowering-for-primary-and-secondary-prevention-of/)
- [Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease](https://scholariq.org/papers/intensive-blood-pressure-control-in-hypertensive-chronic-kidney-disease/)
- [Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m2](https://scholariq.org/papers/comparative-performance-of-the-ckd-epidemiology-collaboration-ckd-epi-and-the/)
- [Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials](https://scholariq.org/papers/change-in-albuminuria-as-a-surrogate-endpoint-for-progression-of-kidney-disease/)
- [Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis](https://scholariq.org/papers/age-stratified-and-blood-pressure-stratified-effects-of-blood-pressure-lowering/)
- [Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy](https://scholariq.org/papers/anti-tgf-1-antibody-therapy-in-patients-with-diabetic-nephropathy/)
- [A meta-analysis of GFR slope as a surrogate endpoint for kidney failure](https://scholariq.org/papers/a-meta-analysis-of-gfr-slope-as-a-surrogate-endpoint-for-kidney-failure/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Parathyroid Disorders and Treatments](https://scholariq.org/topics/parathyroid-disorders-and-treatments/)

## Researcher university

- [Vanderbilt University Medical Center](https://scholariq.org/institutions/vanderbilt-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.